A Phase 2 interventional study of Silodosin 8 mg and Placebo in Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome, sponsored by Watson Pharmaceuticals. Completed at 22 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-02-24.
Sponsored by Watson Pharmaceuticals (part of AbbVie) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Prostatitis with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Prostatitis · United States.
Among the 24 studies in Prostatitis with a site in United States, this one is the 7th largest by enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2008, is one of 6 in phase 2, and was the 10th registered.
89 studies on the registry are indexed under Prostatitis; 12 are open to participants now.
Browse Prostatitis studies →2 of the 24 studies in Prostatitis with a site in United States are open now. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18+
Albany Medical College · Sites in United States
Ages 18–80 · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 6 Prostatitis studies recruiting now, 3 set no upper age limit and 2 stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 3 · Phase 4 5
First in 2003; this study’s year is marked. 3 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 153 is above the median of 61 across 74 interventional studies indexed under Prostatitis.
Median enrollment 62 across the 19 interventional studies, 147 across the 5 observational. Of the 18 that completed or were terminated, 10 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 24 have an industry lead sponsor. The 10 most frequent:
This study is registered under Watson Pharmaceuticals, one of the names counted as AbbVie. Under that name alone:
Watson Pharmaceuticals is the lead sponsor of 30 studies on the registry; none are open to participants now.
AbbVie has 1 study filed under Prostatitis — fewer than ten, so there is no comparison to draw.
1 of the studies in Prostatitis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06299683Vanderbilt University Medical CenterPain Type and Interstitial Cystitis/Bladder Pain Syndrome Treatment | 2027-04-05 |
Add it to your calendar (.ics) → With an account.
Among the 24 studies in Prostatitis with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective is to compare the efficacy of silodosin 4 and 8 mg once daily with placebo in the treatment of subjects with moderate to severe abacterial chronic prostatitis/chronic pelvic pain syndrome during a 12 week treatment period. The secondary objective is to compare the safety of silodosin 4 and 8 mg once daily with placebo.
A Multi-Center, Double-Blind, Placebo-Controlled Investigation of Silodosin in the Treatment of Subjects With Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
4 mg daily
Drug: Silodosin 4 mg
Silodosin 8 mg daily
Drug: Silodosin 8 mg
1 placebo capsule daily
Drug: Placebo
Silodosin 8 mg daily
Also known as: Rapaflo
Placebo
Also known as: Placebo control.
Silodosin 4 mg daily
Also known as: Rapaflo
National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI) Total Score.
Change from baseline In NIH-CPSI at Week 12. Three separate domain scores are calculated as pain, urinary symptoms, and quality of life impact. NIH-CPSI total score uses a 0 to 43 scale; 0 best, 43 worse symptoms.
Time frame: 12 weeks
| Milestone | Silodosin 4 mg | Silodosin 8 mg | Placebo |
|---|---|---|---|
| Started | 52 | 45 | 54 |
| Completed | 43 | 31 | 41 |
| Not completed | 9 | 14 | 13 |
| Withdrew: Adverse event | 4 | 6 | 3 |
| Withdrew: Protocol violation | 1 | 1 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 2 | 4 | 2 |
| Withdrew: Lost to follow-up | 2 | 3 | 5 |
Change from baseline In NIH-CPSI at Week 12. Three separate domain scores are calculated as pain, urinary symptoms, and quality of life impact. NIH-CPSI total score uses a 0 to 43 scale; 0 best, 43 worse symptoms.
| Units on a 0 to 43 scale | Silodosin 4 mg | Silodosin 8 mg | Placebo |
|---|---|---|---|
| Baseline NIH-CPSI Total Score | 26.0 ± 6.29 | 26.8 ± 5.94 | 27.9 ± 6.21 |
| Chage from Baseline in NIH-CPSI at Week 12 | -12.1 ± 9.32 | -10.2 ± 8.84 | -8.5 ± 7.23 |
Collected over 12 weeks. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Silodosin 4 mg | — | 2/52 (3.8%) | 22/52 (42.3%) |
| Silodosin 8 mg | — | 0/45 (0%) | 25/45 (55.6%) |
| Placebo | — | 0/54 (0%) | 12/54 (22.2%) |
| Event | Silodosin 4 mg | Silodosin 8 mg | Placebo |
|---|---|---|---|
| UrosepsisInfections and infestations | 1/52 | 0/45 | 0/54 |
| SyncopeNervous system disorders | 1/52 | 0/45 | 0/54 |
| Event | Silodosin 4 mg | Silodosin 8 mg | Placebo |
|---|---|---|---|
| Retrograde EjaculationReproductive system and breast disorders | 14/52 | 18/45 | 1/54 |
| DizzinessNervous system disorders | 1/52 | 5/45 | 4/54 |
| Nasal CongestionRespiratory, thoracic and mediastinal disorders | 2/52 | 3/45 | 0/54 |
| SinusitisInfections and infestations | 3/52 | 2/45 | 0/54 |
| RashSkin and subcutaneous tissue disorders | 3/52 | 0/45 | 0/54 |
| NauseaGastrointestinal disorders | 0/52 | 0/45 | 3/54 |
| HeadacheNervous system disorders | 1/52 | 2/45 | 2/54 |
| Libido DecreasedReproductive system and breast disorders | 1/52 | 2/45 | 1/54 |
| DiarrhoeaGastrointestinal disorders | 2/52 | 0/45 | 0/54 |
| Neurogenic BladderRenal and urinary disorders | 2/52 | 0/45 | 1/54 |
| Age, Categorical(Participants) | Silodosin 4 mg | Silodosin 8 mg | Placebo | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 44 | 41 | 51 | 136 |
| >=65 years | 8 | 4 | 3 | 15 |
| Age Continuous(years) | Silodosin 4 mg | Silodosin 8 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 49.2 ± 13.34 | 46.7 ± 15.57 | 49.0 ± 11.62 | 48.4 ± 13.43 |
| Sex: Female, Male(Participants) | Silodosin 4 mg | Silodosin 8 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 |
| Male | 52 | 45 | 54 | 151 |
| Region of Enrollment(participants) | Silodosin 4 mg | Silodosin 8 mg | Placebo | Total |
|---|---|---|---|---|
| United States | 52 | 45 | 54 | 151 |
The record gives a start of Sep 2008, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2012, 2 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Silodosin